Invitrogen Licenses Zyomyx Patents; Zyomyx to Help Develop New Protein Chip Products | GenomeWeb

After rebranding itself as a services company (see ProteoMonitor Nov. 19), Zyomyx has exclusively licensed to Invitrogen specific fields of use from over 30 of its protein microarray patents, Invitrogen said this week. The agreement also gave Zyomyx an R&D deal with Invitrogen to help bring new proteomics products to market.

“Invitrogen has outstanding technology for making proteins and content,” said Peter Wagner, the CEO of Hayward, Calif.-based Zyomyx. “In combination with our chip manufacturing process, this is very powerful.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.